Citadel Advisors
AMLX icon

Citadel Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Citadel Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$178K Buy
+12,800
New +$180K ﹤0.01% 11528
2025
Q4 		– Sell
-39,000
Closed -$530K – 12569
2025
Q3 		$530K Buy
+39,000
New +$367K ﹤0.01% 8994
2025
Q2 		– Sell
-35,300
Closed -$125K – 12391
2025
Q1 		$125K Sell
35,300
-89,300
-72% -$318K ﹤0.01% 11151
2024
Q4 		$471K Sell
124,600
-36,100
-22% -$170K ﹤0.01% 8684
2024
Q3 		$521K Buy
160,700
+21,000
+15% +$47.2K ﹤0.01% 8178
2024
Q2 		$265K Sell
139,700
-338,500
-71% -$656K ﹤0.01% 9381
2024
Q1 		$1.36M Buy
478,200
+344,500
+258% +$4.51M ﹤0.01% 6294
2023
Q4 		$1.97M Sell
133,700
-9,400
-7% -$144K ﹤0.01% 5383
2023
Q3 		$2.62M Sell
143,100
-23,100
-14% -$488K ﹤0.01% 4738
2023
Q2 		$3.58M Buy
166,200
+68,600
+70% +$1.85M ﹤0.01% 4163
2023
Q1 		$2.86M Buy
97,600
+9,100
+10% +$316K ﹤0.01% 4716
2022
Q4 		$3.27M Sell
88,500
-149,000
-63% -$5.29M ﹤0.01% 4606
2022
Q3 		$6.69M Buy
237,500
+158,600
+201% +$3.96M ﹤0.01% 3396
2022
Q2 		$1.52M Buy
+78,900
New +$937K ﹤0.01% 6105

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Citadel Advisors's AMLX Position: Q1 2026 in Review

Citadel Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 19% in Q1 2026, buying an estimated $936K and bringing the position to 411,532 shares worth $5.72M. The position accounts for ﹤0.01% of the portfolio, ranked #4124.

Citadel Advisors first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $33M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Citadel Advisors held 411,532 shares of Amylyx Pharmaceuticals worth $5.72M as of Q1 2026.
  • Citadel Advisors bought 66,564 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $936K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4124 holding.
  • Citadel Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Citadel Advisors's Amylyx Pharmaceuticals position peaked at $33M in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.